Lower GI 2017

EXPERT-C Trial

CAPOX All treated (n=81)

CAPOX+C All treated (n=83)

P

14%

18%

pCR (primary endpoint)

.45

CAPOX KRAS/BRAF wild type: n=44

CAPOX+C KRAS/BRAF wild type: n=46

P

51%

73%

After neoadjuvant chemo

.04

76%

89%

After CRT

.12

9.1%

10.9%

At surgery: pCR (+ rCR)

1.0

68%

75%

PFS at 5 years

.23

Dewdney A et al., J Clin Oncol 2012 Sclafani E et al., Eur J Cancer 2014